Is Cytek Biosciences, Inc. (CTKB) Overvalued?
We dive into why Cytek Biosciences, Inc. (CTKB) could be considered overvalued on 2026-08-07, based on AAII’s Value Score and Grade.Jenna Brashear
| SECTOR | INDUSTRY |
| Health Care | Life Sciences Tools & Services |
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
Jenna Brashear
Michael Rose
Michael Rose
Michael Rose
Rosalio Madrigal
| Share Statistics | CTKB | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $605.1 | $3,076.5 | 39% |
|
| Shares Out (Mil) | 129.5 | 96.5 | 68% |
|
| Institutional Ownership | 83.1% | 90.0% | 51% |
|
| Float (Mil) | 103.0 | 71.5 | 62% |
|
| Beta | na | 1.22 | na |
|
| Avg Daily Volume (000s) | 885 | 710 | 68% |
|
| Price Change (52-week) |
15.2% | 89.4% | 58% |
|
| Growth | CTKB | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | 16.8% | 7.8% | 76% |
|
| Net Income (5yr) | (40.3%) | (13.7%) | 9% |
|
| EPS (5yr) | (48.5%) | 0.7% | 4 |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | (15.0%) | (15.0%) | 52% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | na | 1 | 1 | |
| Current EPS | ($0.070) | ($0.120) | $0.070 | |
| Month Ago EPS | $0.030 | ($0.030) | $0.200 | |
| # Rev Up | 0 | 0 | 0 | |
| # Rev Down | 1 | 1 | 1 | |
| Three Months Ago EPS | $0.010 | ($0.040) | $0.190 | |
| Year/Year Chg | (25.5%) | (77.0%) | (130.7%) | |
| Financials | CTKB | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $207 | $800 | 32% |
|
| Net Income (TTM) (Mil) | ($81) | ($31) | 13% |
|
| EPS (TTM) | ($0.627) | ($0.300) | 25% |
|
| Operating Cash Flow (TTM) (Mil) | ($6) | $47 | 24% |
|
| Net Cash Flow (TTM) (Mil) | ($2) | $5 | 38% |
|
| Long-Term Debt (Q1) (Mil) | $14 | $270 | 30% |
|
| Enterprise Value (Q1) (Mil) | na | $3,795 | na |
|
| Valuation | CTKB | Industry Median |
Percentile (All Stocks) |
|
| P/B | 1.88 | 3.68 | 48% |
|
| P/E | na | 39.8 | na |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 5.5 | na |
|
| Ratios | CTKB | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 51.9% | 47.7% | 64% |
|
| Net Margin | (39.0%) | (3.2%) | 13% |
|
| ROA | (17.1%) | (4.3%) | 21% |
|
| ROE | (23.0%) | (7.9%) | 22% |
|
| Liabilities to Assets | 28.0% | 42.0% | 20% |
|
| F-Score | 3 | 5 | na |
|
Cytek Biosciences, Inc. did not pass any screens on 8/20/2026.
Price and market data provided by QuoteMedia and delayed a minimum of 15 minutes unless otherwise indicated. Fundamental data provided by AAII's Stock Investor Pro and S&P Global Market Intelligence and are updated through the previous trading day.
Ⓒ 2026 American Association of Individual Investors